Kornimate/medical-research-clean huggingface dataset:
saphenous vein as y-composite versus aortocoronary conduit for cabg

Conditions: Coronary Artery Disease

Summary: left internal thoracic artery (lita) has been acknowledged as the first graft of choice for coronary artery bypass grafting (cabg). however, it is still not conclusive which one is the best second graft of choice among right internal thoracic artery, radial artery, right gastroepiploic artery, saphenous vein, and etc., as well as its configuration for cabg. in our institution, saphenous vein has been primarily used for the second graft and we have harvested it with 'no touch technique'. we have been demonstrated the excellent long-term patency of this 'no touch saphenous vein' in many studies. however, it is still unknown which configuration is the better strategy for the saphenous vein as a y-composite graft based on the left internal thoracic artery versus an aortocoronary conduit. thus, we aimed to evaluate morphologic change of saphenous vein graft by 1-year intravascular ultrasound (ivus) study and angiographic patency results between y-composite graft and aortocoronary conduit.

the enrolled patient underwent routine sternotomy, and left internal thoracic artery (lita) and saphenous vein (sv) are harvested. after harvest, the patient is randomized to y-composite group or aortocoronary group. for y-composite group, sv is anastomosed to lita as y-composite fashion. then, lita is anastomosed to left anterior descending artery. sv is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posterior descending artery). for aortocoronary group, lita is anastomosed to left anterior descending artery. then, sv is anastomosed to ascending aorta using proximal anastomosis assist device without clamping the aorta. sv is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery). at 1-year follow-up, coronary angiography is performed to evaluate the patency of the saphenous vein graft. clinical outcomes are also evaluated.

Eligibility criteria:
inclusion criteria: * a patient who is going to receive coronary artery bypass grafting * older than 19 years * coronary artery bypass grafting is going to be performed with left internal thoracic artery and saphenous vein graft exclusion criteria: * other concomitant procedures (e.g. valve or aorta surgery) is planned * patients with severe comorbidities which limit the life expectancy of them below 1 year (e.g. terminal cancer) * patients whose left internal thoracic artery or saphenous vein is not available due to the low quality, severe injury, or absence of the graft * patients whose ascending aorta is not suitable to aortocoronary anastomosis (e.g. ascending aorta aneurysm, porcelain aorta) * emergency operation * patients who have connective tissue disease * reoperative coronary artery bypass grafting

Keywords: coronary artery bypass grafting saphenous vein coronary angiography
effectiveness of the fibulock intramedullary nail

Conditions: Fibula Fracture

Summary: the objective of this post-market clinical study is to evaluate efficacy outcomes and complication rates in patients who have received the fibulock™ intramedullary nail.

this is a retrospective/prospective, multi-site observational study, designed to evaluate the clinical outcomes and complication rates in subjects who were previously implanted with a fibulock™ intramedullary nail. patients will be screened for eligibility and subgroupings. informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. sites will be asked to enroll subjects according to past treatment, with the fibulock™ intramedullary nail for unstable fibula fracture. the sites will enroll subjects in the study based on inclusion/exclusion criteria. patient pre-operative, intra-operative and post-operative records will be reviewed retrospectively. once enrolled, subjects will undergo an evaluation of fracture outcome and complete a vas pain score, sf-12, and foot function index at 26 weeks and again at 52 weeks post-treatment.

Eligibility criteria:
inclusion criteria: * an unstable fibula fracture. * must be less than 31 weeks post-implantation * must have received surgical treatment with the fibulock intramedullary nail for their unstable fibula - fracture * male or female greater than or equal to 18 years of age and skeletally mature. * able to understand the requirements of the study, provide a written informed consent and comply with the study protocol * ability to understand and provide written authorization for use and disclosure of personal health information. exclusion criteria: * patients who are not implanted with a sonoma fibulock im nail
characterization of biliary cell-derived organoids from bile of psc and non-psc patients

Conditions: Primary Sclerosing Cholangitis; PSC; Cholangiocarcinoma

Summary: the purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with primary sclerosing cholangitis (psc) and controls to learn more about changes that occur in the liver.

the study will ask participants to provide bile and/or bile duct cytology brushings at time of endoscopic retrograde cholangiopancreatography (ercp) or cholecystectomy (gallbladder removal). the bile and brushings will be used to generate and perpetuate bile-derived organoids using an established matrigel-based protocol. these organoids will then be used in downstream experiments to better understand disease-specific alterations to biological pathways informative of disease pathogenesis

Eligibility criteria:
inclusion criteria: psc * patients diagnosed with psc between the age of 18 and 85. * the diagnosis of psc will be based on standard psc criteria including clinical and biochemical evidence of chronic cholestasis of at least six months duration, positive cholangiographic findings and compatible liver biopsies if available. * women with psc of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation. patients with psc and cholangiocarcinoma will be included. controls • controls without history of psc or evidence of other chronic liver disease of either gender that will participate in this study should be between the ages of 18-85. exclusion criteria: * patients unable to provide inform consent. * prisoners and institutionalized individuals. * psc with orthotopic liver transplantation * history of roux en y procedure
treatment of nosebleeds in the emergency department with powder tranexamic acid

Conditions: Epistaxis Nosebleed

Summary: nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. to stop a nosebleed in the emergency department, doctors usually have to burn the nose (called cauterization) or insert pledgets (called nasal packing) into the nose to apply direct pressure to the bleeding site. nasal packing can cause pain and discomfort at the time it is inserted in the nose and again when it is removed. in rare cases it can cause a range of complications: minor complications include scar bands in the nose, but serious complications of nasal packing have also occurred, including death. nasal packing can also present risks to doctors, such as the risk of contracting airborne and bloodborne infections, like covid-19 and hiv. tranexamic acid in pill form or given directly into a vein is a medication that is currently used for nosebleeds. this study looks to evaluate if tranexamic acid in powder form sprayed directly in the nose can be used as an alternative to cauterization or nasal packing for the treatment of nosebleeds.


Eligibility criteria:
inclusion criteria: * capable of giving informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * adults 18 years or older * male or female * presenting to the ed with active, spontaneous epistaxis. anterior versus posterior epistaxis will be identified a priori. anterior epistaxis is operationally defined as active nasal bleeding that occurs anterior to the anterior limit of the middle turbinate, visible by anterior rhinoscopy. exclusion criteria: * prior sinonasal surgery within the preceding 1 month. * patients who required medical treatment for epistaxis in the preceding 30 days. * septum perforation. * known history of bleeding disorders, including thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von willebrand disease. * history of known thromboembolic disease, including subarachnoid hemorrhage, stroke, or tia. * known history of disease of the central nervous system, including seizures, convulsions, or intra-cerebral disease processes/lesions. * known or suspected history of significant skull base trauma, including skull base fracture or cerebrospinal fluid leak. * known history of acquired disturbances of colour vision. * known hematuria or any bleeding related to the kidney. * pregnant and/or lactating women. * history of known allergy or sensitivity to the study medication. * presence of signs or symptoms of concomitant emergent conditions, including myocardial infarction, stroke, major trauma, shock, or hemodynamic instability. * patients with other medical conditions including cognitive limitations or impairment due to substance abuse. * patients with any other condition that, in the opinion of the investigator, may present an unreasonable risk to the patient, may make the patient unreliable, or may interfere with the study assessments. * current participation in another interventional clinical trial.
randomized control trial of small-molecule natural flavonoids intervention for neurodegenerative diseases

Conditions: Neurodegenerative Diseases

Summary: 1. explore the effects of natural plant flavonoids on the positive intervention mechanism of neurotransmitter transmission physiological indicators changes (eeg) in the brain of the study subjects; 2. investigate the effects of natural plant flavonoids in positively intervening clinical symptoms of the study subjects.


Eligibility criteria:
inclusion criteria: 1. age: 25-70 years 2. patients complaining of sleep disorders, mood disorders (unstable mood, irritability, depression, and anxiety), and cognitive decline (people with memory, decreased reaction time, bpsd symptoms) within one month 3. montreal cognitive assessment scale (moca) score ≤26; if the moca score is not satisfied, then pittsburgh sleep quality index (psqi) score \>10 and hamilton anxiety scale (hama) score \>14 or hamilton depression scale (hamd) score ≥8 are required 4. patients who can understand and communicate in language, and complete aphasia patients are not included; 5. patients who agree to participate in this clinical observation and sign the informed consent form. exclusion criteria: 1. patients with severe organ diseases such as heart, kidney, and liver failure, chronic lung diseases such as copd, and severe diabetes; 2. patients with severe uncontrolled hypertension; 3. patients who have taken antipsychotic drugs within the past two weeks; 4. patients with the core features of lewy body dementia or significant behavioral variant frontotemporal dementia; 5. patients with various malignant tumors; 6. patients with progressive stroke, transient ischemic attack, cerebral hemorrhage after cerebral infarction, and cerebral arteritis; 7. patients with brain tumors, brain trauma, cerebral parasitic diseases, and other conditions; 8. pregnant or lactating women; 9. patients allergic to the known ingredients used in this trial; 10. patients with active ulcers or bleeding tendencies; 11. patients with neurodegenerative diseases such as huntington's disease, amyotrophic lateral sclerosis, and pick's disease; 12. other patients who are deemed unsuitable to participate in this trial by the investigators.
outcomes study of late effects after proton rt for pediatric tumors of the brain, head, and neck

Conditions: Central Nervous System Tumors

Summary: the purpose of this study is to collect information from medical records to see what effects proton beam radiation has on cancer and analyze possible side effects.

data collection will be obtained from the patient's medical records including initial evaluation, radiotherapy completion records and follow-up.

Eligibility criteria:
inclusion criteria: * estimated \>5 cc of the brain tissue to receive \>5 cge radiation * patient must be less than 21 years of age at time of consent. * patients that require localized and craniospinal irradiation. * patients and/or patient parent must complete baseline quality of life questionnaire as applicable by patient age group. exclusion criteria: * prior radiation therapy. * evidence of metastases outside the central nervous system.

Keywords: proton radiation central nervous system (cns) tumors brain spine cancer radiation therapy (rt)
assessment of lateral and vertical tissue displacement obtained by the retraction cord and diode laser

Conditions: Endodontically-Treated Teeth; Spacing of Anterior Maxillary Teeth; Broken Teeth Injury With Complication

Summary: in fixed prosthodontic treatment, deflection of gingival tissues for diagnosis or making an impression is one of the important phases. gingival displacement is defined as "displacement of gingival tissues both in vertical and lateral dimensions". lateral retraction displaces the tissues so that an adequate bulk of impression material can be interfaced with the prepared tooth. vertical retraction exposes the uncut portion of the tooth apical to the finish line conventional gingival retraction cord technique may injure the healthy epithelial lining and result in postoperative gingival recession the diode laser has been used for displacing gingiva to make a deﬁnitive impression. rather than displacing gingival tissue, it removes the epithelial lining from the sulcus. the aim of the study is to compare between the ultrapak retraction cord and diode laser regarding the amount of vertical and lateral retraction and patient comfort.


Eligibility criteria:
inclusion criteria: * age range of the patients from 20-45 years old; able to read and sign the informed consent document, illiterate patient will be avoided. * patients able physically and psychologically to tolerate conventional restorative procedures. * patients with no active periodontal disease. * patients with thick gingival biotype. * patients with teeth problems indicated for full coverage restoration . * vital or non vital teeth. * good oral hygiene. exclusion criteria: * patients with poor oral hygiene. * patients with thin gingival biotype. * pregnant women. * unmotivated patients. * patients with gingival recession. * patients with psychiatric problems or unrealistic expectation . * patient suffer from parafunctional habit . * smokers and heavy caffeine consumers.

Keywords: gingival retraction gingival displacement diode laser
mirtazapine versus placebo in functional dyspepsia

Conditions: Functional Dyspepsia

Summary: double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg daily or placebo, followed by 8 weeks of open-label mirtazapine 15 mg daily

double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg or placebo, followed by 8 weeks of open-label mirtazapine two weeks run-in, 8 weeks randomized, 8 weeks open label assessments include * dyspepsia questionnaire * nepean dyspepsia index * daily diary * vital signs

Eligibility criteria:
inclusion criteria: * functional dyspepsia according to rome ii criteria * weight loss of \> 5% body weights exclusion criteria: * organic gi pathology * history of upper gi tract surgery * major depression or anxiety * use of antidepressants in the last 2 months * prokinetic drugs or spasmolytic drugs * analgesic use (except paracetamol) * pregnancy or lactation

Keywords: functional dyspepsia weight loss mirtazapine
randomized controlled trial of the effects of electroacupuncture preconditioning in children undergoing cardiac surgery

Conditions: Congenital Heart Defects

Summary: the purpose of this study is to determine whether electroacupuncture preconditioning would provide protection against myocardial ischemic-reperfusion injury and systemic inflammation in children undergoing cpb for repair of congenital heart defects.

2-12 years old children undergoing repair of congenital heart defects were included, except for those with server pulmonary arterial hypertension, chromosomal defects, airway and parenchymal lung disease, immunodeficiency, or blood disorders were excluded. children were equal randomized to eapc(electroacupuncture preconditioning)or control group. electroacupuncture was administered on the bilateral p6 acupoint after anesthesia induction, but prior to surgery in eapc group. control patients underwent sham placement of the electrode the arm without stimulation. the duration of cardiopulmonary bypass and aortic cross-clamp time was recorded. myocardial injury was assessed by cardiac heart-type fatty acid-binding protein (hfap) and cardiac troponin i (ctni\>0.40 ng/ml). 8-isoprostane , c-reactive protein, cytokines were measured pre- and postoperatively.

Eligibility criteria:
inclusion criteria: * aged 2-12 years children undergoing repair of congenital heart defects without server pulmonary arterial hypertension or systematic disease. * get an informed consent from parental. exclusion criteria: * patient's age is less than 2 years or more than 12 years. * patient with isolated atrial septal defect undergoing repair via thoracoscope completion. * patients with chromosomal defects, airway and parenchymal lung disease, immunodeficiency, or blood disorders. * patients without an informed consent from parental.

Keywords: electroacupuncture pediatric cardioprotection
traditional chinese medicine in the supportive management of anaemic and cytopenic (leukopenia, thrombocytopenia) haematological disorders

Conditions: Myelodysplastic Syndrome (MDS); Aplastic Anaemia (AA); Myelofibrosis (MF); Thalassemia Intermedia

Summary: the purpose of this study is to study the efficacy of traditional chinese medicine (tcm) on anaemic and cytopenic haematological disorders including myelodysplastic syndrome (mds), aplastic anaemia (aa), myelofibrosis (mf) and thalassemia intermedia who do not have or did not respond to available treatment options.


Eligibility criteria:
inclusion criteria: 1. a diagnosis of mds, aa, mf or thal based on currently recognized diagnostic criteria. 2. explored or undergone established therapies eg haemopoietic stem cell transplant, immunosuppressive therapy, chemotherapy, growth factors, thalidomide, hypomethylating agent or androgens, and (a) are deemed not suitable, or (b) refuse or (c) have failed therapy 3. a preceding follow up period (without or with treatment) of 2-4 months as baseline (depending on the severity of cytopenia) before being enrolled into this study 4. understand the trial nature of this treatment, agree to be compliant to medication, do not self medicate and have signed informed consent 5. agreeable to regular blood tests and follow up marrow study as listed in schedule exclusion criteria: 1. life expectancy of shorter than one year 2. significant organ failure including the following 3. renal impairment with cr above 200umol/l 4. liver impairment with serum bilirubin \> 2x upper limits or transaminase \>3x upper limits 5. escalation of treatment of introduction of new agents including growth factors, thalidomide, hypomethylating agents, immunosuppressive therapy or androgens once started on treatment with tcm is not allowed. continuation of current therapy at same or lower doses is allowed 6. women during pregnancy or lactation.

Keywords: chronic cytopenic haematological diseases chinese herbal concoction supportive management
optimal dosage of caspofungin in critically ill patients

Conditions: Critically Ill; Suspected Invasive Candidiasis

Summary: intensive care unit (icu) patients are especially at risk for invasive candidiasis due to the presence of risk factors. it is known that in critically ill patients, alterations in function of various organs and body systems can influence the pharmacokinetics and hence the plasma concentration of a drug. a study of caspofungin in icu patients has found a high inter- and intra-individual variability in caspofungin concentration. factors that caused subtherapeutic caspofungin plasma concentrations were body weight \> 75 kg and hypoalbuminemia. furthermore, an efficacy study showed a lower response rate for caspofungin among patients with a higher disease severity score. as a result of the altered pharmacokinetics, under- or over-exposure of caspofungin can occur in critically ill patients and an adjusted dosage might be necessary in these patients.


Eligibility criteria:
inclusion criteria: * treatment with caspofungin. * admission to an icu. * age ≥ 18 years. * suspected invasive candidiasis, established by the physician. exclusion criteria: * blood sampling by central venous catheter or peripheral cannula not possible.
evaluation of lixisenatide efficacy in diabetes mellitus type 2 with failure of other glp-1 analog

Conditions: Diabetes Mellitus Type 2

Summary: the study aims to examine the effectiveness of the short acting glp-1 analog, lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting glp-1 analog. patients who fail to achieve significant improvement in diabetes control on basal insulin and liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. the primary outcomes will be changes in hba1c and weight.


Eligibility criteria:
inclusion criteria: type diabetes mellitus on combination of basal insulin therapy and glp1 analog, with secondary failure of non-fasting glycemic control exclusion criteria: * pregnant or lactating woman * renal failure (egfr\<30)

Keywords: type 2 diabetes mellitus treatment glp-1
efficacy of cilostazol in prevention of peripheral neuropathy

Conditions: Peripheral Neuropathy; Breast Cancer

Summary: there are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. one of the main mechanisms is induction of schwann cell dedifferentiation by paclitaxel. at the preclinical level, cilostazol potently inhibited paclitaxel-induced dedifferentiation of cultured schwann cells, yet this positive effect have not been clinically investigated.


Eligibility criteria:
inclusion criteria: 1. breast cancer patients who will receive paclitaxel post-anthracycline therapy. 2. eastern cooperative oncology group (ecog) performance status from 0 to 2. 3. adequate bone marrow function (white blood count ≥4,000/mm3, platelet count≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine \< 1.5 mg/dl). exclusion criteria: 1. patients with signs and symptoms of clinical neuropathy at baseline. 2. patients with diabetes mellitus or alcoholic disease. 3. patients receiving vitamin/ supplementation drugs that interfere with the study intervention.